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Neuroblastoma immunotherapy using cytokine-modified tumour cells has been tested in clinical trials. However, because of the
complex nature of antitumour immune responses, a number of therapies may be required for complete tumour eradication and
generation of systemic immunity. We report here the improved antitumour effect of two cytokines, interleukin-2 (IL-2) and
interleukin-12 (IL-12), when coexpressed by neuroblastoma cell lines. Initially, transfection of human and mouse neuroblastoma cell
lines resulted in high expression levels of biologically active IL-2 and IL-12 in vitro. These cytokines when expressed by transfected
Neuro-2A cells completely abolished their in vivo tumorigenicity in a syngeneic neuroblastoma model. Vaccination of established
tumours with IL-12-producing cells exhibited a clear effect with reduced tumour growth in the presence of IL-2. In vivo depletion
studies showed that CD4
þ and CD8
þ T cells mediate the response against cytokine-producing cells. These results suggest that IL-2
and IL-12, when cotransfected in tumour cells, are effective against established disease and provide a promising immunotherapeutic
approach for the treatment of neuroblastoma.
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Neuroblastoma is one of the most common solid tumours
occurring in children. Prognosis of the disease ranges from
spontaneous regression for Stage IV S patients to other forms
associated with relapse and low survival rates when it occurs as
disseminated disease. Neuroblastoma therapy depends on the
stage of the disease, but has mainly consisted of chemotherapy
followed by surgical resection of the tumour or radiotherapy
(Pinkerton et al, 2000). Strategies to address the minimal residual
disease have included high-dose chemotherapy with autologous
haematopoietic stem cell rescue or differentiation of the remaining
malignant cells with retinoids (Philip et al, 1997). However, the
success rate has been limited and thus alternative strategies
including immunotherapy are under investigation (Bowman et al,
1998).
Inflammatory cytokines such as interleukin-2 (IL-2) and
interleukin-12 (IL-12) have been explored for the treatment of
cancers (Parmiani et al, 2000; Rosenberg, 2001). Interleukin-12 is a
potent activator of natural killer (NK) cells and T lymphocytes, and
promotes the development of CD4
þ Th1-inducing antitumour
immunity (Trinchieri, 1998). Many of its functions are mediated
through the actions of IFN-g, but it has also been shown to
synergise with IL-2 to generate lymphokine-activated killer (LAK)
cells against tumour targets (Cameron et al, 1990). Interleukin-2
has shown antitumour activity in a number of studies mainly
because of its ability to activate and enhance the cytolytic activity
of NK and T cells (Fearon et al, 1990; Gansbacher et al, 1990).
Interleukin-2 and -12 have both distinct and overlapping effects
on a wide range of immune cell types. They work synergistically on
NK cells through the upregulation of IL-12 receptors and STAT4
by IL-2 (Wang et al, 2000). Interleukin-12 induces CD25
expression on T cells, thereby enhancing their proliferation in
response to IL-2 (Nguyen et al, 2000). Natural Killer cells treated
with a combination of IL-2 and IL-12 exhibit enhanced in vitro
cytolytic activity and lyse neuroblastoma cells (Rossi et al, 1994)
and human osteosarcoma cells more efficiently (Mariani et al,
2000). Furthermore, the combination of these two cytokines has
proved successful in the treatment of Lewis lung carcinoma
(Tanaka et al, 2000).
We have previously described LID, a synthetic vector that
consists of a lipid (L), an integrin-targeting peptide (I), and a DNA
component (D) that transfects a number of cell types with high
efficiency (Hart et al, 1998). This vector exploits the ubiquitous
expression of integrin receptors on the surface of most cell types as
a means of binding and entry. A further advantage of this system is
that it is not limited by DNA size constraints, as is usually the case
with viral systems. The aim of the current study was to use this
nonviral vector to deliver genes encoding IL-2, IL-12, or a
combination of these cytokine genes, to neuroblastoma cells in
an attempt to develop a therapeutic cellular vaccine.
Neuroblastoma cell lines, transfected ex vivo with the LID
vector, were able to express high levels of IL-2 and IL-12, even if
cotransfected with other cytokine genes. These cytokines exhibited
in vitro biological activity and reduced the tumorigenicity of
neuroblastoma cells in a mouse model. Also, the combination of
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was capable of eradicating established tumours and exhibited a
greater antitumour effect than either cytokine alone.
MATERIALS AND METHODS
Cell culture
The human neuroblastoma cell lines SHSY-5Y, IMR-32, and
the mouse cell line Neuro-2A (N2A), derived from a spontaneous
neuroblastoma tumour in A/J mice, were obtained from
the American Tissue Culture Collection (ATCC) or the European
Collection of Cell Cultures (ECACC). They were cultured
in Dulbecco’s modified Eagle medium (DMEM-Glutamax-1)
(Life Technologies, Paisley, UK) supplemented with 10% foetal
bovine serum (Sigma Chemical Co, Dorset, UK), 1% nonessential
amino acids, 100IUml
 1 penicillin and 100mgml
 1 streptomycin,
and 1% sodium pyruvate (all from Life Technologies, Paisley, UK).
The hybridoma cell lines YTS191.1 and YTS169 were a gift from
Dr Baker (Institute of Neurology, London, UK) and produce
rat (IgG2b) anti-mouse CD4 and CD8 antibodies, respectively.
Cells were cultured in RPMI containing 10% FCS, 2mM
glutamine, and 10mgml
 1 gentamicin until confluent. The
medium was then replaced with Hybridoma-SFM medium (Life
Technologies, Paisley, UK) containing 10mgml
 1 gentamicin for
48h.
Plasmid DNA
The pEGFP-N1 plasmid encodes the gene for the green fluores-
cence protein and was obtained from Clontech (CA, USA). The
plasmid pCMV-Flexi12 encodes the cDNA for both human IL-12
genes (p35 and p40) as a fusion protein (Anderson et al, 1997).
pCI-IL2 plasmid carrying the human IL-2 cDNA was constructed
by incorporation of the hIL2 cDNA into the EcoRI–NotI restriction
sites of the pCI plasmid (Promega, Southampton, UK). The cDNA
for both genes of murine IL-12 were carried on the expression
vector pCDNA3.1scIL12 with a linker and expressed as a fusion
protein [a gift from Professor Reisfeld (The Scripps Research
Institute, CA, USA)] (Lode et al, 1998). All plasmids were
propagated in E. coli DH5a and purified on Hybaid columns
according to the manufacturer’s instructions (Hybaid, Ashford,
UK).
Optimisation of neuroblastoma cell line transfection
with the LID vector
Cells were seeded in a 48-well plate at a concentration of 2.5 10
4
cells per well and transfected using the LID vector, as described
previously, using 1mg of DNA per well (Hart et al, 1998). LD
complexes were prepared by mixing Lipofectin with plasmid DNA
at a weight ratio of 5:1. All complexes were incubated for 1.5h at
RT prior to transfecting the cells for 4h. Previous studies (Hart
et al, 1998) showed that all the three vector components were
required for maximum transfection efficiency. Transfections of
neuroblastoma cells with the full LID formulation were signifi-
cantly more efficient than those with LD or ID complexes
(Po0.05) (data not shown). The most consistent transfection
efficiency was achieved by an a5b1 integrin-specific peptide
(peptide 6), whose binding domain RRETAWA was isolated from
a phage display library (Koivunen et al, 1994).
FACS analysis
Transfection efficiency of neuroblastoma cells with pEGFP-N1
plasmid vector was estimated through fluorescence-activated cell
sorting (FACS) analysis. The cells were transfected as described
above in 48-well plates using the pEGFP-N1 vector and analysed
48h post-transfection using a FACS sorter (FACSCalibur, Beckton
Dickinson, Oxford, UK) and Cell Quest software.
Analysis of cytokine production
Transfection of neuroblastoma cells with the cytokine expression
vectors was carried out in 24-well plates using peptide 6. The
supernatant from transfected cell lines was collected at 24h
intervals and quantitation of IL-2 or IL-12 was performed using a
DuoSet ELISA Development System (R&D Systems, Oxford, UK)
according to the manufacturer’s instructions.
Cell proliferation assays
Mononuclear cells from the peripheral blood of healthy donors
were obtained by density gradient centrifugation on Ficoll-Paque
(Amersham Pharmacia Biotech, St Albans, UK). These cells were
monocyte-depleted by plastic adherence and then resuspended at
10
7cellsml
 1 in RPMI 1640 medium (Life Technologies, Paisley,
UK) containing 2.5mgml
 1 PHA (Sigma Chemical Co, Dorset, UK)
and cultured for 3 days as described previously (Anderson et al,
1997). rhIL-2 (50IUml
 1) (R&D Systems, Oxford, UK) was added
for a further 24h and 50ml of cell suspension (4 10
5cellsml
 1)
was incubated with the supernatant of transfected neuroblastoma
cells. Cell proliferation was measured after incubation with
3H-labelled thymidine (0.5mCi per well) for 16h.
Animal studies
All animal procedures were approved and licensed by the Home
Office and performed according to the standards required by the
UKCCCR (Workman et al, 1998). A/J mice were obtained from
Harlan Laboratories (UK). gc/RAG2 knockout mice were a gift
from JP Di Santo (Pasteur Institute, Paris, France) (Goldman et al,
1998). A/J (n¼6 per group) or gc/RAG2 knockout mice (n¼3 per
group) were inoculated subcutaneously in the posterior flank with
10
6 N2A cells transfected with LID vector complexes containing
cytokine genes or control plasmid, or were untransfected. For
vaccination of established tumours, tumour formation was
induced by subcutaneous inoculation of 10
6 wild-type N2A cells.
Palpation was performed to examine tumour size, which reached a
diameter of B5mmat1071 days post-inoculation. Subcutaneous
tumour growth was monitored using callipers by measuring their
diameter every 2–3 days. Animals were killed when tumours
reached a diameter of 417mm, which was defined as the survival
end point. In vivo T- and NK-cell immunodepletion experiments
were performed by intraperitoneal administration of 350mg rat
IgG2a anti-mouse CD4
þ, anti-CD8
þ,o r4 0ml rabbit anti-asialo GM
(Wako, Neuss, Germany), respectively, into A/J mice on days  6,
 3, þ2, and every 5 days thereafter. The anti-CD4
þ and anti-
CD8
þ antibodies were purified from the culture supernatant of
YTS191.1 and YTS169 hybridoma cells on HiTrap Protein G
columns (Amersham Pharmacia Biotech, St Albans, UK) according
to the manufacturer’s recommendations and dialysed with PBS. On
the day of tumour inoculation, the splenocytes of one animal per
group were stained for CD4, CD8, and/or NK cells, in order to
confirm immunodepletion using rat FITC-conjugated anti-mouse
CD4, anti-CD8, and pan-NK or NK 1.1 antibodies (Pharmingen,
San Diego, CA, USA). Flow cytometric analysis was performed as
described above.
Statistical analysis
The nonparametric Mann–Whitney test was used to assess the
significance between different experimental groups. For cytokine
production and bioassays, comparison among different groups
was performed at each time point.
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Cytokine expression by neuroblastoma cell lines
LID transfection was optimised for the human and mouse
neuroblastoma cell lines. In all cases, the most efficient vector
formulation consisted of an a5b1 integrin-targeting peptide and
lipofectin, as described in the Materials and Methods. Transfection
of neuroblastoma cell lines with the plasmid pEGFP-N1 encoding
the green fluorescent protein (GFP) reporter gene, using the LID
vector, was highly efficient and ranged from 47% for SHSY5Y to
64% for N2A and IMR-32 cells.
Cytokine expression was studied after transfecting human
neuroblastoma cell lines IMR-32 and SHSY5Y with pCI-IL2 vector
and/or pCMV-Flexi12 (human) (Anderson et al, 1997), while the
mouse Neuro-2A cell line was transfected with pCDNA3.1scIL12
(mouse) (Lode et al, 1998) and/or pCI-IL-2. For both transfected
IMR-32 and SHSY5Y cell lines, IL-12 expression followed a stable
pattern with a slight reduction in expression on day 5 in the latter
cell line. Transfection experiments using single cytokine genes
resulted in significantly higher production of IL-12 than in
experiments where IL-2 and IL-12 genes were cotransfected
(Po0.05), despite the fact that equal amounts of each cDNA were
used to transfect these cells. Nevertheless, hIL-12 levels in double
transfections were sustained above 45ng24h
 110
 6 cells in IMR-
32 (Figure 1A) and 10ng24h
 110
 6 cells in SHSY5Y cell line
(Figure 1C) throughout the 10-day period. Murine IL-12 expres-
sion by mouse N2A cells was sustained at a fairly constant level
throughout the seven days of analysis with no significant
difference between single (53076ng24h
 110
 6 cells) and co-
transfection experiments (513.6717ng24h
 110
 6 cells) (P40.05)
(Figure 1E).
Human IL-2 secretion by human neuroblastoma cell lines
reached a peak 24–48h post-transfection in both cell lines, with
IMR-32 cells expressing 349.775.5ng24h
 110
 6 cells (Figure 1B)
and SHSY5Y cells 14.371.25ng24h
 110
 6 cells (Figure 1D).
There was a slight decrease in hIL-2 levels after day 5 but
expression was maintained above 5ng24h
 110
 6 cells at least up
to 10 days of culture. The levels of hIL-2 secreted by N2A cells were
higher, starting at 385ng24h
 110
 6 cells and dropping to
170ng24h
 110
 6 cells by day 7 of the analysis (Figure 1F). In
all experiments, there was minimal detectable production of
cytokines by pEGFP-N1-transfected cells (Po0.04).
The biological activity of IL-2 and IL-12 produced by
the neuroblastoma cells was tested on PHA-stimulated peripheral
blood lymphocytes. Undiluted supernatant from cytokine-trans-
fected cells was applied onto PHA-activated lymphocytes for
24h prior to
3H-labelled thymidine addition. The proliferative
effect of the cytokines on PHA-activated lymphocytes after
incubation with
3H-labelled thymidine for 16h was examined.
Biologically active IL-2 was secreted by transfected SHSY5Y and
IMR-32 cells up to 5 days post-transfection (Po0.05), although
there was a decline in the H
3-labelled thymidine incorporation
into PHA-stimulated lymphocytes after day 2 (Figure 2). IL-2
expressed by transfected Neuro-2A cells exhibited an increasing
proliferative effect on activated lymphocytes, which reached a
plateau by day 5 and was significantly higher than supernatant
from control transfectants (Po0.05). Human IL-12 secreted
by transfected SHSY5Y and IMR-32 cells over a period of at least
10 days in vitro showed a stable level of biological activity
compared to control supernatant (Po0.05). From 48h after
transfection of Neuro-2A cells with murine IL-12, cytokine levels
in the supernatant were sufficient to induce a significant
proliferative effect on PHA-activated lymphocytes, which persisted
throughout the 5-day analysis period (Po0.06). Furthermore, the
supernatant from all neuroblastoma cell lines transfected with
genes for both IL-2 and IL-12 exhibited a significant mitogenic
effect compared to control supernatant (Po0.05), indicating that
cotransfection results in expression of biologically active cytokines
for at least 10 days in vitro.
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Figure 1 In vitro IL-2 and IL-12 expression by LID-transfected neuroblastoma cell lines. Neuroblastoma cells were transfected using an a5b1-specific
peptide and pCI-IL2, pCMVFlexi-12, or pCDNA3.1scIL12 plasmids. Cytokine expression was monitored over a period of 10 days by collecting the cell
culture supernatant at 24h intervals and assaying the cytokine levels by ELISA. Human IL-2 (A) and IL-12 (B) secretion by transfected IMR-32 cells; (C), (D)
SHSY5Y cell line; (E), (F) hIL-2 and murine IL-12 expression by transfected N2A cells, respectively. Solid lines represent transfections with a single cytokine
gene, and dotted lines represent experiments where both cytokine genes were introduced into the cells. Error bars represent standard deviations from
triplicate transfections and one representative experiment is shown.
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neuroblastoma cells
To establish whether the cytokines produced by neuroblastoma
cells were biologically active in vivo and to test the vaccine in the
A/J mouse model of neuroblastoma, 6–8-week-old mice were
inoculated subcutaneously with 10
6 unmodified or cytokine-
transfected N2A cells. Mice receiving cells transfected with IL-12
or a combination of IL-2 and IL-12 remained tumour free for at
least 75 days. Interleukin-2-secreting N2A cells also failed to grow
tumours in 83% of the animals compared to mice that received
untransfected cells that developed tumours within 12 days of the
injection (Figure 3). The tumorigenicity of cytokine-transfected
cells in A/J mice was reduced significantly (Po0.05) compared to
cells transfected with the control plasmid. However, 33% of
animals inoculated with cells transfected with plasmid control
remained tumour free. We determined whether transfection was
altering the proliferative potential of the cells by
3H-thymidine
incorporation. No differences were observed among untransfected,
cytokine- or vector-transfected N2A cells, suggesting that transfec-
tion itself did not influence the cells’ in vivo tumour-forming
potential (data not shown).
The requirement for secreted cytokines for an antitumour effect
was determined by performing tumourigenicity experiments in
which groups of A/J mice (n¼6) were coinjected with viable N2A
cells (10
6) and with a dilution series (10
3–10
6 cells) of N2A-IL-
2þIL-12 cells. The control group consisted of animals receiving
only wild-type N2A cells (10
6). A complete antitumour effect was
observed with N2A-IL-2þIL-12 expressing 235ng IL-12 and 40ng
IL-2 (Figure 4). However, efficient antitumour protection (83%)
were achieved with 118ng IL-12 and 20ng IL-2, while for 50%
tumour growth inhibition a minimal 12ng IL-12 and 2ng IL-2 was
required.
Eradication of established tumours
The effect of cytokine-transfected N2A cells on established
tumours was examined by inducing subcutaneous neuroblastoma
tumours in A/J mice by inoculation of 10
6 wild-type N2A cells.
When a minimal tumour was palpable (approximately 5mm
diameter), the animals received an intratumoral vaccination with
10
6 vector or cytokine-transfected N2A cells that had been
previously irradiated (25Gy). Irradiation of cells reduced their
in vitro proliferation, but did not significantly alter their cytokine
expression levels compared to nonirradiated transfected N2A cells
(data not shown). Tumour growth in vaccinated animals was
monitored every 2 days. The tumours of mice vaccinated with
vector-transfected or IL-2-transfected N2A cells rapidly reached a
diameter of 417mm and had to be killed, 16.871.4days and
17.370.9days post-vaccination, respectively (Figure 5A). There
was significant survival enhancement when vaccination was
performed with N2A-IL-2þIL-12 (25.377days; Po0.03) or
N2A-IL-12 cells (31717days; Po0.05) compared to N2A-vector
cells.
Interestingly, the N2A-IL-12 and the N2A-IL-2þIL-12 vaccines
exhibited similar levels of efficiency of eradication (27 and 33%,
respectively) on established tumours. However, in addition to mice
displaying tumour eradication, a further 58% of N2A-IL-2þIL-12-
vaccinated animals responded to vaccination by tumour growth
inhibition. In contrast, only 36% of animals, that received the N2A-
IL-12 vaccine, showed tumour growth delay despite higher IL-12
expression levels, while the tumours in the remaining animals
(37%) grew aggressively. This indicated that vaccination with N2A-
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with 91% of treated animals displaying tumour eradication or
retarded growth, compared with cells expressing IL-12 alone,
where only 63% of treated animals showed one of these responses
(Figure 5B).
Involvement of CD4 and CD8 T cells in the initial immune
response against tumour cells expressing IL-2 and IL-12
The mechanism of cytokine-mediated tumour cell rejection was
assessed in tumourigenicity studies performed in gc/RAG2 knock-
out mice, which lack any T, B, or NK cells (Goldman et al, 1998).
Subcutaneous administration of N2A-IL-2þIL-12 transfectants
into gc/RAG2 knockout mice showed tumour growth kinetics
similar to those of N2A-vector cells (Figure 6A). This indicated
that abrogation of tumourigenicity of N2A-IL-2þIL-12 cells was
an immunological phenomenon. To further specify the effector
population responsible for the rejection of N2A-IL-2þIL-12 cells,
we performed immunodepletion studies in A/J mice. Mice (n¼6)
were depleted of either CD4
þ, CD8
þ, CD4
þ and CD8
þ,o rN K
cell subsets as described in Materials and Methods or received PBS
as a control. Prior to inoculation of N2A-IL-2þIL-12 cells, one
animal per group was killed to confirm the extent of immunode-
pletion (data not shown). Depletion of CD8
þ T cells did not have
an effect on the tumourigenicity of N2A-IL-2þIL-12 cells until day
25 when 33% of the immunodepleted animals grew tumours, while
mice receiving PBS as a control remained tumour free. This
indicated that these effector cells were at least partly involved in
the rejection of N2A-IL-2þIL-12 transfectants (Figure 6B).
Depletion of NK cells in A/J mice with anti-asialo GM antibody
did not induce tumour formation with viable N2A-IL-2þIL-12
cells, whereas depletion of both CD4
þ and CD8
þ T-cell
populations resulted in aggressive tumour formation in all animals
(Figure 6C). Interestingly, the kinetics of tumour formation by
N2A-IL-2þIL-12 cells in CD4
þ- and CD8
þ-depleted mice showed
a slight time delay compared to those of N2A-vector cells,
suggesting that depletion is incomplete or that NK cells are active.
DISCUSSION
Evasion of the host immune surveillance may contribute to tumour
development. A number of mechanisms have been proposed to
explain the failure of the immune system to attack tumour growth
including downregulation or absence of MHC, costimulatory
molecules or other antigen-processing machinery, secretion of
inhibitory cytokines, or loss of immunodominant antigens.
Whatever the mechanism, immunotherapy has emerged as a
promising approach for the eradication of parental tumours and
generation of long-term immunity (Foss, 2002; Paul et al, 2002).
The processes of tumour development and eradication are
complex and still poorly understood. Different cytokines affect
the immune response in different ways and therapeutic efficacy
depends on a number of steps from the initial tumour-specific
immune activation to the development of long-lasting protective
immunity. In many cases, combinations of cytokines or coexpres-
sion of MHC or costimulatory molecules have proved more
efficient in recruiting inflammatory cells to the tumour site,
resulting in the eradication of established animal tumours (Putzer
et al, 1997; Addison et al, 1998; Chong et al, 1998).
Current therapy for neuroblastoma consists of surgical resec-
tion, radiation, or chemotherapy with a mean disease-free survival
of 3 years (Philip et al, 1997; Pinkerton et al, 2000). However,
because of the high incidence of relapse, more effective treatments
targeting minimal residual disease and metastases formation are
required. This was addressed in a study with an anti-GD2 antibody
fused to murine IL-12 (Lode et al, 1998). Also, patient clinical trials
using IL-2 gene-modified autologous tumour cells have shown
antitumour responses with antibody production and
MHC-restricted cytotoxicity against autologous tumour cells
(Bowman et al, 1998).
The use of a combination of IL-2 and IL-12 is supported by a
number of studies indicating that cancer eradication is a complex
process and might require recruitment of multiple cytokines or
costimulatory molecules. Peripheral blood mononuclear cells from
neuroblastoma patients showed increased cytotoxic activity when
activated in vitro with both cytokines than with IL-2 or IL-12 alone
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Figure 5 Effect of vaccination on established murine tumours. A/J mice
(n¼11–12 per group) were subcutaneously inoculated with 10
6 parental
N2A cells and 9–11 days later vaccinated directly into the tumour with an
equal number of irradiated (25Gy) vector- or cytokine-transfected N2A
cells. The tumour growth in each animal was monitored and is represented
by a single line (A). The overall antitumour response combining tumour
growth inhibition and tumour eradication are also shown (B). Data from
two separate experiments were combined.
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s(Rossi et al, 1994). Furthermore, a synergistic combination
between IL-2 and IL-12 was observed in a Lewis lung carcinoma
model where only vaccination with dual-gene transduced cells
inhibited growth of established tumours (Tanaka et al, 2000). In
the current study using a nonviral vector system, cytokine
expression by transfected neuroblastoma cell lines peaked around
48h after transfection. Codelivery of two cytokine genes carried on
different plasmids resulted in the production of biologically active
cytokines. Also, the cytokine levels secreted by transfected
neuroblastoma cell lines were comparable to levels reported for
adenoviral vectors (Leimig et al, 1996). For the purpose of a
tumour vaccine, such cytokine levels were shown to be adequate
for immunomodulation despite the transient nature of transfection
(Balicki et al, 2000).
The IL-2 and IL-12 cytokines secreted by transfected N2A cells
were not only capable of inducing in vitro proliferation of PHA-
activated lymphocytes, but also exhibited biological activity
in vivo. Following inoculation into syngeneic A/J mice, N2A cells
transfected with cytokines (mIL-12, hIL-2, or a combination of the
two) exhibited significantly reduced tumorigenicity compared to
untransfected or vector control-transfected cells, which formed
aggressive tumours and had to be killed by 12 days. This effect was
not because of reduced cell proliferation as shown by in vitro
3H-labelled thymidine incorporation, but was rather a specific
effect of cytokine expression. In vivo the cytokine levels required
for complete tumour growth inhibition by parental N2A cells were
235ng/24h IL-12 and 40ng/24h IL-2. Significant antitumour
protection was, however, achieved with N2A-IL-2þIL-12 cells
expressing 118ng IL-12 and 20ng IL-2.
Studies in gc/RAG2 knockout mice indicated that rejection of
N2A cells expressing a combination of IL-2 and IL-12 was an
immunological phenomenon. Natural Killer depletion in A/J mice
had no effect on tumour formation by N2A-IL-2þIL-12 cells,
suggesting that this effector cell population is not involved in the
rejection of N2A-IL-2þIL-12 cells. Further in vivo depletion
studies in A/J mice showed that rejection of N2A-IL-2þIL-12
transfectants was mediated partly by CD8
þ T cells. However,
depletion of both T cell subsets completely abrogated the
immunogenicity of N2A-IL-2þIL-12 cells, suggesting a tumour
rejection mechanism involving CD8
þ T-cell activation by CD4
þ T
cells. Most cancer vaccines will be used on patients with primary
tumours or on those who, after initial treatment, have relapsed
with metastatic disease. Therefore, the most clinically relevant
aspect of a cancer vaccine is its efficacy on established disease. We
examined the immunological effect of irradiated N2A cells
expressing IL-2, IL-12, or a combination of the two cytokines on
parental tumours. The N2A-IL-2þIL-12 vaccine exhibited a
higher overall antitumour response compared to either cytokine
used alone. It was effective in most treated animals inducing either
tumour regression (33%) or delay in tumour growth (58%), with
an overall response rate of 91%. When IL-12 was used on its own,
it resulted in similar tumour regression with the N2A-IL-2þIL-12
vaccine with 27% of the tumours undergoing complete regression
and an overall response of just 63%, while 37% of animals
receiving the IL-12 vaccine grew aggressively. Interestingly, IL-2
alone did not exhibit any antitumour efficacy, despite the fact that
it totally abrogated the in vivo tumorigenicity of IL-2-transfected
N2A cells. Although we were not able to determine the reason for
the absence of tumour growth by N2A-vector cells in two out of six
animals, vector-related rejection events have been reported
previously (Todryk et al, 1999).
Although only local vaccine administration was addressed
in this study, the biological efficacy of the N2A-IL-2þIL-12
vaccine and its ability to be used against established disease
was verified. Further optimisation would be required and
alternative vaccine administration routes would have to be tested,
however, before such a treatment is considered for clinical use. In
addition, it should be emphasised that the antitumour effects of the
N2A-IL-2þIL-12 vaccine were a result of single vaccination
experiments. The observation that the majority of N2A-IL-2þIL-
12-vaccinated tumours exhibited a delay in tumour growth
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Figure 6 Tumorigenicity of N2A-IL-2þIL-12 transfectants in gc/RAG2
knockout (A) or in immunodepleted (B, C) mice. Administration of anti-
CD4 or anti-CD8 antibodies was performed separately (B) or coadminis-
tered (C) intraperitoneally twice before inoculation of N2A-IL-2þIL-12
cells and every 5 days thereafter. Natural Killer cell depletion was
performed by i.p. Inoculation of anti-ASGM1 antibody and control group
consisted of PBS-injected animals. Tumour growth of N2A-IL-2þIL-12
cells in immunodepleted mice was compared with mock-transfected N2A-
cells (N2A-vector). The mean tumour volume of six mice per group is
presented.
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ssuggests that repeated vaccination is probably required for
complete regression.
The improved antitumour effect shown by the combination of
IL-2 and IL-12 suggests that an inflammatory cytokine, such as IL-
12 functions to attract effector cells at the vaccination site and
activate APCs. Its antitumour immunity has also been shown to
include non-T-cell-mediated events (Nastala et al, 1994) and
angiostatic effects (Voest et al, 1995). Histological examination of
vaccinated tumours revealed infiltration of CD45
þ cells compared
to N2A-vector-treated animals (data not shown). A second
cytokine, such as IL-2, that is capable of clonally expanding
activated T cells, may be vital for strengthening the immune
response against the tumour and achieving long-term immunity.
Indeed, tumour-targeted IL-2 has been shown to be capable of
amplifying CD8
þ T cells after IL-12 vaccination and enhancing
MHC I-mediated killing in a murine model of neuroblastoma
metastasis (Lode et al, 1999). Despite the reported synergy between
IL-2 and IL-12 on NK cells (Wang et al, 2000), immunodepletion
studies in A/J mice suggested that NK cells did not play a major
role in the rejection of IL-2þIL-12-transfected N2A cells.
Consistent with our findings, IL-2 and IL-12 may work together
on T-cell activation (Nguyen et al, 2000). The complete abrogation
of immunogenicity of N2A-IL-2þIL-12 cells, when both T-cell
subsets are depleted, supports the latter hypothesis.
In conclusion, in this study, we have shown that coexpression of
IL-2 and IL-12 offers improved antitumour immunity in a murine
model of neuroblastoma and provides a potential approach for the
treatment of neuroblastoma. Also, the proposal that multimodality
therapies against cancer may prove more efficient is supported by
these findings.
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